Human IL-2 ELISA Kit
The IL-2 ELISA is to be used for the in-vitro quantitative determination of interleukin-2. (IL-2) in human serum, plasma, buffered solutions or cell culture medium.
IL-2 is a powerful immunoregulatory lymphokine produced by T-Cells in response to antigenic or mitogenic activation. IL-2 stimulates growth and differentiation of B-Cells, most T-cells, NK cells, monocytes and macrophages.
Mature IL-2 is a 15.4kDa globular glycoprotein containing 133 amino acid residues including one intrachain disulfide bond between residues 58 and 105.
A polyclonal antibody specific for IL-2 has been coated onto the wells of the microtiter strips provided.
During the first incubation, IL-2 present in the sample or standard and a monoclonal anti IL-2 antibody conjugated to biotin are simultaneaously incubated.
Following incubation unbound biotinylated anti-IL-2 is removed during a wash step.
Streptavidin-HRP is added and binds to the biotinylated anti IL-2. After incubation and a wash step a substrate solution reactive with HRP is added to the wells.
- Sobjanek, M. et al., Postepy Dermatol Alergol.,2016; 33(4): 263-8.
- Altokka-Uzun, G. et al., Cephalalgia, 2015: 333102415570762
- Gritzapis, A. D. et al., Br J Cancer,2003; 88(8): 1292-300
- Hadley, E. A. et al.,Clin Exp Immunol.,2005; 140(1): 101-8
- Hohn, H. et al., Clin Exp Immunol.,2003; 131(1): 102-10
- Kerr J. et al., J. Gen. Virol., 2001; 82(Pt 12): 3011-3019
- Montcuquet, N. et al., Immunology,2008;125(3): 320-30.
- Nagao, Y. et al., Malar J.,2008; 7: 113. Rodriguez-Zapata, M. et al., Infect. Immun.,2010; 78:3272-3279
- Saverino D. et al., J. immunol., 2002; 168(1): 207 – 215
- Stebbing, J. et al., Clin Exp Immunol.,2004; 138(2): 312-6.
- Tang, Y. et al., Am J Trop Med Hyg.,2008; 79(2): 154-158.
- Trznadel-Grodzka, E. et al., Postepy Hig Med Dosw (Online),2012; 66: 843-7
- Trznadel-Grodzka, E. et al., Postepy Hig Med Dosw (Online),2012; 66: 848-54
- Buenestado, A. et al., J Parenter Enteral Nutr.,2006;30(4):286-96
- Eilertsen, G. O. et al., Lupus,2011 ; 20(6): 607-613.
- Azadbakht, L. et al., Diabetes Care,2007;30(4):967-73
- Blanco B. et al., J. Immunol., 2003 ; 171(2):1070-7
- Blanco, B. et al., Blood, 2006;107(9):3575-83
- Calabia-Linares, C. et al., J. Cell Sci.,2011; 124(5): 820-830
- Casati, C. et al., Cancer Res.,2003;63(15):4507-15
- Doniz-Padilla, L. et al., Eur. J. Endocrinol.,2011 ; 165(1): 129-136.
- Ge, N. L. et al., World J Gastroenterol.,2003; 9(10): 2182-5
- Giaccone, G. et al., Clin Cancer Res., 2002; 8 (12): 3702-9 Guo, Z. et al., Biomed Rep.,2016;5(5): 567-573
- Kapsogeorgou E.K. et al., J. Immunol., 2001; 166(5): 3107 – 3113
- Kashyap, B. et al., J Trop Pediatr., 2011:fmr093
- Liu, C. P. et al., J Leukoc Biol., 2007; 81: 1276 – 1286
- Llorente, L. et al., Arthritis Rheum.,2000;43(8):1790-800
- Martin-Cofreces, N. B. et al., J Immunol., 2006;176(7):4201-7
- Martin-Cofreces, N. B. et al., J. Cell Biol.,2008; 182(5): 951-962.
- Merlo, A. et al., Infect Immun.,2001;69(10):6022-9
- Ralph, C.et al.,Clin. Cancer Res.,2010;16(5): 1662-1672
- Robles-Valero, J.et al., Blood,2010; 115(21): 4174-4184.
- Rybka, J. et al.,Clin Exp Med.,2015; 16(4): 493-502.
- Saifullah, S. Khan, et al.,Chem Cent J.,2013;7:163
- Shaw, D. M. et al.,Br J Cancer,2007; 96(4): 567-74.
- Stebbing, J. et al., Ann Oncol.,2003;14(11):1660-6
- Su,C-C et al., Cancer Res., 2004; 64(6): 2148 – 2152
- Sun, Z. et al.,Cent Eur J Immunol.,2014;39(2): 216-22
- Tiemessen M.M. et al., Int. Immunol., 2003; 15(12): 1495 – 1504
- Urso, K. et al., Blood, 2011; 118: 795 – 803
- van der Burg, S. H. et al., PNAS,2007; 104(29): 12087-12092.
- Woerly G. et al., J. Exp. Med., 1999; 190(4): 487 – 495
- Rai, G. et al.,Ann Lab Med., 2018 Mar;38(2):125-131
- Harwood, S.L. et al.,Oncoimmunology. 2017 Sep 27;7(1):e1377874.
- Owens, G.L. et al.,J Immunother. 2018 Apr;41(3):130-140